

UPDATE ON MYELOYDYSPLASTIC SYNDROME

An Essay

*Submitted for partial fulfillment of
The Master Degree in Clinical and Chemical Pathology*

By

Ahmed Mahmoud A. Abdellatif
(M.B., B.Ch 2002)

Under Supervision of

Prof. Dr. Afaf AbdelAziz AbdelGhaffar

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Dr. Sahar Samir AbdelMaksoud

*Assistant Professor of Clinical and Chemical
Pathology*

Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University
2008*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿قَالُوا سُبْحَانَكَ لَا عِلْمَ
لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ
أَنْتَ الْعَلِيمُ الْحَكِيمُ﴾

صدق الله العظيم

البقرة/ آية (٣٢)

Acknowledgment

First and foremost, I am very grateful to Allah, the most Gracious, the most Merciful, who granted me the ability to perform this essay.

I would like to express my deepest gratitude and sincere thanks to Professor Doctor / Afaf AbdelAziz AbdelGhaffar, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her support, supervision, generous encouragement and guidance, Her scientific generosity contributed a lot to the final shape of this work, I appreciate very much her wisdom, understanding and most valuable suggestions.

No word can ever express my profound gratitude and my ultimate thanks to Doctor / Sahar Samir AbdelMaksoud, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her skillful participation, continuous advice, and for her efforts in assisting me throughout the whole work,

Ahmed M. Abdellatif

2008

Table of Contents

LIST OF ABBREVIATIONS	VII
LIST OF TABLES	VIII
LIST OF FIGURES	IX
INTRODUCTION.....	1
AIM OF THE WORK	3
REVIEW OF LITERATURE	5
HISTORICAL BACKGROUND OF MYELOYDYSPLASTIC SYNDROME	7
INCIDENCE OF MYELOYDYSPLASTIC SYNDROME	12
ETIOLOGY OF MYELOYDYSPLASTIC SYNDROME.....	14
MDS RELATED TO ENVIRONMENT AND OCCUPATION	15
THERAPY-RELATED MDS	16
FAMILIAL MDS	19
PATHOBIOLOGY OF MYELOYDYSPLASTIC SYNDROME	20
STEM CELL CHANGES	20
ROLE OF APOPTOSIS IN MDS PATHOGENESIS	23
IMMUNOLOGICAL ABNORMALITIES IN MDS.....	25
CLINICAL AND LABORATORY DIAGNOSIS OF MYELOYDYSPLASTIC SYNDROME.....	26
CLINICAL FEATURES.....	26
COMPLETE BLOOD COUNT (CBC)	29
PERIPHERAL BLOOD SMEAR	30
BONE MARROW ASPIRATE	34
BONE MARROW BIOPSY	41
IMMUNOHISTOCHEMICAL DETECTION IN BONE MARROW BIOPSY SECTIONS	45
FLOW CYTOMETRY IN MDS	50
KARYOTYPING IN MDS	53
<i>Common chromosomal abnormalities described in MDS.....</i>	<i>56</i>
1) Chromosome 5 abnormalities	56
2) Chromosome 7 abnormalities	60

3) Del(20q).....	62
4) Loss of Y (-Y).....	63
5) Loss of 17p "17p- syndrome".....	64
6) Chromosome 11 abnormalities	65
7) Trisomy 8 (+8).....	66
8) Del(12)(p13)	67
9) Chromosome 3 abnormalities	68
10) Complex karyotypes	69
<i>Fluorescence in situ hybridization in MDS</i>	70
MOLECULAR TYPING AND POINT MUTATION ANALYSIS IN MDS	72
OTHER RECOMMENDED INVESTIGATIONS	74
DIFFERENTIAL DIAGNOSIS OF MDS	77
RECENT UPDATE ON MDS DIAGNOSIS.....	79
1) <i>National Comprehensive Cancer Network guidelines for initial evaluation of patients with suspected MDS</i>	79
2) <i>Minimal diagnostic criteria recently proposed for diagnosis of MDS</i>	82
CLASSIFICATION OF MYELOYDYSPLASTIC SYNDROME	86
THE FRENCH-AMERICAN-BRITISH (FAB) CLASSIFICATION SYSTEM.....	86
<i>Limitations of the FAB system</i>	89
THE WORLD HEALTH ORGANIZATION (WHO) CLASSIFICATION SYSTEM	91
<i>Controversies regarding the WHO classification</i>	96
WHO CLASSIFICATION OF THE MYELOYDYSPLASTIC/MYELOPROLIFERATIVE DISEASES (MDS/MPD).....	99
CLASSIFICATION OF PEDIATRIC MDS	101
PROGNOSIS OF MYELOYDYSPLASTIC SYNDROME.....	103
THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM.....	103
<i>Limitations of the IPSS</i>	106
ADVERSE PROGNOSTIC FACTORS IN MDS	107
TREATMENT OF MYELOYDYSPLASTIC SYNDROME.....	108
SUPPORTIVE TREATMENT OF MDS.....	108
SPECIFIC THERAPY CLASSES.....	112
STEM CELL TRANSPLANTATION.....	114
SUMMARY AND CONCLUSION.....	117
REFERENCES.....	121
ARABIC SUMMARY.....	141

List of Abbreviations

AA	APLASTIC ANEMIA
AIHA	AUTOIMMUNE HEMOLYTIC ANEMIA
ALIPs	ABNORMAL LOCALIZATION OF IMMATURE PRECURSORS
ALL	ACUTE LYMPHOBLASTIC LEUKAEMIA
AML	ACUTE MYELOID LEUKEMIA
CDS	COMMONLY DELETED SEGMENTS
CML	CHRONIC MYELOGENOUS LEUKEMIA
CMML	CHRONIC MYELOMONOCYTIC LEUKEMIA
CMV	CYTOMEGALOVIRUS
EPO	ERYTHROPOIETIN
FAB	FRENCH-AMERICAN-BRITISH
FEP	FREE ERYTHROCYTE PROTOPORPHYRIN
FISH	FLUORESCENCE IN SITU HYBRIDIZATION
G-CSF	GRANULOCYTE COLONY STIMULATING FACTOR
GEP	GENE EXPRESSION PROFILING
GM-CSF	GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR
HLA	HUMAN LEUKOCYTE ANTIGEN
HUMARA	HUMAN ANDROGEN RECEPTOR ASSAY
IHC	IMMUNOHISTOCHEMISTRY
IPSS	INTERNATIONAL PROGNOSIS SCORING SYSTEM
LDH	LACTATE DEHYDROGENASE
JMML	JUVENILE MYELOMONOCYTIC LEUKEMIA
MDS	MYELODYSPLASTIC SYNDROME
MDS/MPD	MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISORDER
M:E	MYELOID-TO-ERYTHROID RATIO
mFISH	MULTICOLOR FLUORESCENCE IN SITU HYBRIDIZATION
MGUS	MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE
MIC	MORPHOLOGIC-IMMUNOLOGIC-CYTOGENETIC STUDY GROUP
MPD	MYELOPROLIFERATIVE DISORDER
PCR	POLYMERASE CHAIN REACTION
PNH	PAROXYSMAL NOCTURNAL HEMOGLOBINOPATHY
PRCA	PURE RED CELL APLASIA
RA	REFRACTORY ANEMIA
RAEB	REFRACTORY ANEMIA WITH EXCESS BLASTS
RAEB-T	REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION
RARS	REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS
RCMD	REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA
RCMD-RS	REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA WITH RINGED SIDEROBLASTS
t-MDS	THERAPY-RELATED MDS
u-MDS	UNCLASSIFIABLE MDS
WHO	WORLD HEALTH ORGANIZATION

List of Tables

TABLE (1)	CHRONOLOGY AND TERMINOLOGY OF MDS.....	11
TABLE (2)	MORPHOLOGICAL ABNORMALITIES SEEN IN BLOOD SMEAR IN MDS	32
TABLE (3)	MORPHOLOGICAL ABNORMALITIES SEEN IN BONE MARROW SMEAR IN MDS	37
TABLE (4)	RECOMMENDED IMMUNOHISTOCHEMICAL MARKERS IN MDS	46
TABLE (5)	VALUE OF BONE MARROW HISTOLOGY AND IMMUNOHISTOCHEMISTRY IN MDS (AND RECOMMENDED TESTS).....	49
TABLE (6)	RECURRENT PHENOTYPIC ABNORMALITIES DETECTED BY FLOW CYTOMETRY IN MDS.....	52
TABLE (7)	COMMON CHROMOSOMAL ABNORMALITIES SEEN IN MDS.....	54
TABLE (8)	OTHER RECOMMENDED INVESTIGATIONS IN MDS.....	74
TABLE (9)	NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES FOR INITIAL EVALUATION OF PATIENTS WITH SUSPECTED MDS.....	80
TABLE (10)	MINIMAL DIAGNOSTIC CRITERIA FOR MDS	83
TABLE (11)	FAB CLASSIFICATION OF MDS	87
TABLE (12)	WHO CLASSIFICATION OF MDS.....	94
TABLE (13)	WHO CLASSIFICATION OF THE MDS/MPD.....	99
TABLE (14)	CLASSIFICATION OF PEDIATRIC MDS.....	102
TABLE (15)	THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM	105
TABLE (16)	ADVERSE PROGNOSTIC FACTORS IN MDS.....	107

List of Figures

FIGURE (1)	DIFFERENT FACETS OF THE SAME MDS CLONE.....	21
FIGURE (2)	HYPOTHETICAL MODEL OF MULTISTEP DEVELOPMENT OF MDS	22
FIGURE (3)	POSSIBLE EXPLANATION OF THE PARADOXICAL FINDING IN MDS	24
FIGURE (4)	THE SPECTRUM OF CLINICAL MANIFESTATIONS IN MDS	28
FIGURE (5)	PSEUDO-PELGAR-HUET FORM	33
FIGURE (6)	MONOCYTOSIS IN MDS	33
FIGURE (7)	DYSERYTHROPOIESIS IN MDS.....	38
FIGURE (8)	DYSGRANULOPOIESIS IN MDS	38
FIGURE (9)	MICRO MEGAKARYOCYTE	39
FIGURE (10)	RING SIDEROBLASTS, IDENTIFIED BY PRUSSIAN BLUE STAIN.....	39
FIGURE (11)	HOWELL-JOLLY BODY IN AN ERYTHROBLAST.....	40
FIGURE (12)	MYELOID BLAST WITH AN AUER ROD.....	40
FIGURE (13)	TECHNIQUE OF BONE MARROW BIOPSY FROM THE POSTERIOR ILIAC SPINE.....	41
FIGURE (14)	RELATIVE PERCENTAGE OF VARIOUS CYTOGENETIC ABNORMALITIES IN de NOVO MDS.	55
FIGURE (15)	del(5)(q13q33) AS AN EXAMPLE OF CHROMOSOME 5 ABNORMALITIES.....	57
FIGURE (16)	del(7)(q11q36) AS AN EXAMPLE OF CHROMOSOME 7 ABNORMALITIES.....	60
FIGURE (17)	PROPOSED ALGORITHM FOR MDS DIAGNOSIS ACCORDING TO THE FAB CLASSIFICATION.....	88
FIGURE (18)	SPLITTING OF THE FAB GROUPS RA AND RARS AS WARRANTED BY THE WHO CLASSIFICATION.....	92
FIGURE (19)	PROPOSED ALGORITHM FOR MDS DIAGNOSIS ACCORDING TO THE WHO CLASSIFICATION	95

INTRODUCTION

Myelodysplastic syndrome (MDS) comprises a group of clonal hematologic disorders characterized clinically and morphologically by ineffective hematopoiesis. The natural history of this syndrome ranges from a chronic course that may span years to a rapid course of leukemic progression (***Shadduck et al., 2007***).

Unfortunately, the nomenclature and classification systems used to describe these conditions are cumbersome and contentious. Nonetheless, MDS are viewed by most hematologists as encompassing stages of neoplastic hematopoiesis associated with cytopenias and as excluding nonneoplastic conditions. In general, myelodysplastic conditions are preleukemic disorders in which the neoplastic clone is established, but not all cases of myelodysplasia terminate in acute myeloid leukemia (AML) (***Heaney and Golde, 1999***).

Neoplastic transformation of hematopoietic cells can occur at various levels of stem-cell development (***Mueller et al., 2003***).

The initial hematopoietic stem cell injury can result from cytotoxic chemotherapy, radiation exposure, viral infection, chemical exposure, or genetic predisposition. A clonal mutation predominates over bone marrow suppressing healthy stem cells (**Cheson et al, 2000**).

A thorough diagnostic evaluation is a prerequisite for therapeutic decision-making. Parallel use of the older French-American-British (FAB) and the newer World Health Organization (WHO) classifications is helpful in evaluating patients with MDS (**Deeg, 2005**).

Cytogenetic studies have revealed both balanced chromosomal abnormalities leading to the generation of fusion oncogenes and unbalanced recurrent aberrations, most commonly -5 , $5q-$, -7 , $7q-$, $+8$, $11q-$, $13q-$ and $20q-$ suggesting that genes within these regions have a role in MDS pathogenesis (**Look, 2005**).

The decision about how to deal with the morbidity of the disease versus the potential benefits and toxicities from treatment will ultimately be made by the individual patient. This decision is based on age, personal preferences, and available information about

disease biology and prognostic factors (*Hellström-Lindberg, 2005*).

Aim of the work

The aim of the present work is to review recent advances in myelodysplastic syndrome as regard molecular pathogenesis, diagnosis, classification and treatment.